论文部分内容阅读
目的比较神经节苷脂与依达拉奉治疗急性脑出血的临床疗效。方法选取2014年5月—2016年5月南京市江宁医院收治的急性脑出血患者80例,采用随机数字表法分为对照组和观察组,每组40例。在常规治疗基础上,对照组患者给予依达拉奉治疗,观察组患者给予神经节苷脂治疗;两组患者均连续治疗2周。比较两组患者临床疗效及治疗前后美国国立卫生研究院卒中量表(NIHSS)评分、日常生活能力量表(ADL)评分。结果观察组患者临床疗效优于对照组(P<0.05)。两组患者治疗前NIHSS评分、ADL评分比较,差异无统计学意义(P>0.05);观察组患者治疗后NIHSS评分低于对照组,ADL评分高于对照组(P<0.05)。结论神经节苷脂治疗急性脑出血的临床疗效优于依达拉奉,能够更有效地改善患者神经功能及日常生活能力。
Objective To compare the clinical efficacy of ganglioside and edaravone in the treatment of acute cerebral hemorrhage. Methods Eighty patients with acute cerebral hemorrhage admitted to Nanjing Jiangning Hospital from May 2014 to May 2016 were randomly divided into control group and observation group with 40 cases in each group. On the basis of routine treatment, patients in the control group were treated with edaravone, and patients in the observation group were treated with ganglioside. Patients in both groups were treated continuously for 2 weeks. The clinical efficacy of the two groups was compared before and after treatment with the National Institutes of Health Stroke Scale (NIHSS) score, daily living ability scale (ADL) score. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). There was no significant difference in NIHSS score and ADL score between the two groups before treatment (P> 0.05). The NIHSS score of the observation group was lower than that of the control group after treatment, and the ADL score was higher than that of the control group (P <0.05). Conclusion Ganglioside is superior to edaravone in the treatment of acute intracerebral hemorrhage. It can improve neurological function and daily life more effectively.